Differential effects of ontamalimab versus vedolizumab on immune cell trafficking in intestinal inflammation and IBD

ABSTRACT: The anti-MAdCAM-1 antibody ontamalimab demonstrated efficacy in a phase II trial in UC and results of early terminated phase III trials are pending, but its precise mechanisms of action are still unclear. Thus, we explored the mechanisms of ontamalimab and compared it to the anti-α4β7 antibody vedolizumab.

ORGANISM(S): Mus musculus

PROVIDER: GSE230059 | GEO | 2023/06/05

REPOSITORIES: GEO